A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations

被引:3
|
作者
Kobayashi, Hiroaki [1 ]
Kosaka, Takeo [1 ]
Nakamura, Kohei [2 ]
Shojo, Kazunori [1 ]
Hongo, Hiroshi [1 ]
Mikami, Shuji [3 ]
Nishihara, Hiroshi [2 ]
Oya, Mototsugu [1 ]
机构
[1] Keio Univ, Dept Urol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan
[2] Keio Univ, Keio Canc Ctr, Genom Unit, Sch Med, Tokyo, Japan
[3] Keio Univ, Div Diagnost Pathol, Sch Med, Tokyo, Japan
关键词
Ductal adenocarcinoma; Neuroendocrine prostate cancer; Next-generation sequencing; Case report; CANCER; DIFFERENTIATION;
D O I
10.1186/s12920-021-01093-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Ductal adenocarcinoma and neuroendocrine cancer are rare subtypes of prostate cancer with poor prognosis and limited therapeutic options. We present the first case of ductal adenocarcinoma having a neuroendocrine phenotype. Case presentation A 63-year-old man presented with gross hematuria and urinary retention, and his serum prostate-specific antigen level was 4.58 ng/mL. We performed transurethral resection of the prostate, and the diagnosis was ductal adenocarcinoma with a Gleason score of 5 + 4 for acinar adenocarcinoma. Magnetic resonance imaging showed local invasion of left lobe of the prostate and bone metastasis of the left trochanteric section of the femur. Multidisciplinary treatments such as androgen deprivation therapy, chemoradiation therapy, and surgery for metastatic lesions have led to long-term survival. Since next-generation sequencing revealed PTEN and RB1 co-loss and TP53 mutations, we re-evaluated the immunohistochemistry and he was found to be positive for synaptophysin. Conclusions This is the first Japanese case of ductal adenocarcinoma with a neuroendocrine phenotype. Genetic analysis may help not only guide the therapeutic strategies, but also sometimes with the diagnosis.
引用
下载
收藏
页数:5
相关论文
共 50 条
  • [21] Clinical impact of mutations in driver oncogenes and TP53/RB1 in advanced prostate cancer.
    Hammer, Liat
    Rebernick, Ryan
    McFarlane, Matthew
    Westbrook, Thomas
    Hazime, Munna
    Hammoud, Tanya
    Chiu, Pin-en
    Xavier, Owens
    Wu, Yi-Mi
    Robinson, Dan R.
    Spratt, Daniel Eidelberg
    Alva, Ajjai Shivaram
    Jackson, William C.
    Reichert, Zachery R.
    Alumkal, Joshi J.
    Chinnaiyan, Arul
    Cieslik, Marcin
    Dess, Robert Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [22] Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy
    Lu, Yiyu
    Li, Zhihua
    Zhu, Huawei
    Zhao, Juan
    Xu, Mian
    Gu, Weiguang
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (12) : 12886 - 12893
  • [23] Molecular alterations of the RB1, TP53, and MDM2 genes in primary and xenografted human osteosarcomas
    Pellin, A
    Boix-Ferrero, J
    Carpio, D
    Lopez-Terrada, D
    Carda, C
    Navarro, S
    Peydro-Olaya, A
    Triche, TJ
    Llombart-Bosch, A
    DIAGNOSTIC MOLECULAR PATHOLOGY, 1997, 6 (06) : 333 - 341
  • [24] Clinical and Molecular Characteristics of EGFR Mutant Lung Cancers with Concurrent TP53 and RB1 Mutations
    Offin, M.
    Tenet, M.
    Shen, R.
    Rekhtman, N.
    Rizvi, H.
    Hellmann, M.
    Arcila, M.
    Ladanyi, M.
    Rudin, C.
    Kris, M.
    Yu, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S412 - S412
  • [25] PHENOTYPIC-GENOTYPIC CORRELATION OF TP53 AND RB1 IN UROTHELIAL CARCINOMA
    Audenet, Francois
    Isharwal, Sumit
    Zheng, Xiaoyong
    Jordan, Emmet
    Iyer, Gopa
    Lee, Byron
    Cha, Eugene
    Donahue, Timothy
    Donat, Machele
    Herr, Harry
    Dalbagni, Guido
    Bochner, Bernard
    Berger, Michael
    Solit, David
    Al-Ahmadie, Hikmat
    JOURNAL OF UROLOGY, 2017, 197 (04): : E644 - E644
  • [26] Development and validation of a gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
    Torras, Oscar Reig
    Jimenez, Natalia
    de Herreros, Marta Garcia
    Aversa, Caterina
    Marin, Mercedes
    Ferrer, Laura
    Rodriguez-Carunchio, Leonardo
    Trias, Isabel
    Fernandez-Manas, Laia
    Garcia-Esteve, Samuel
    Pous, Albert Font
    Rodriguez-Vida, Alejo
    Domenech-Santasusana, Montserrat
    Figols, Mariona
    Climent, Miguel Angel
    Costa, Sara Cros
    Chirivella, Isabel
    Rivera, Daniel Herrero
    Suarez, Cristina
    Mellado-Gonzalez, Begona
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [27] Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20%
    Konukiewitz, Bjoern
    Schlitter, Anna Melissa
    Jesinghaus, Moritz
    Pfister, Dominik
    Steiger, Katja
    Segler, Angela
    Agaimy, Abbas
    Sipos, Bence
    Zamboni, Giuseppe
    Weichert, Wilko
    Esposito, Irene
    Pfarr, Nicole
    Kloeppel, Guenter
    MODERN PATHOLOGY, 2017, 30 (04) : 587 - 598
  • [28] IDH-mutant astrocytomas with primitive neuronal component are aggressive tumors characterized by alterations in RB1 and TP53
    Slocum, C.
    Hickman, R.
    Gedvilaite, E.
    Ptashkin, R.
    Brannon, R.
    Ladanyi, M.
    Miller, A.
    Pentsova, E.
    Tabar, V.
    Young, R.
    Mellinghoff, I.
    Rosenblum, M.
    Bale, T.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2023, 82 (06): : 522 - 523
  • [29] Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients
    Jimenez, Natalia
    de Herreros, Marta Garcia
    Reig, Oscar
    Marin-Aguilera, Mercedes
    Aversa, Caterina
    Ferrer-Mileo, Laura
    Garcia-Esteve, Samuel
    Rodriguez-Carunchio, Leonardo
    Trias, Isabel
    Font, Albert
    Rodriguez-Vida, Alejo
    Climent, Miguel Angel
    Cros, Sara
    Chirivella, Isabel
    Domenech, Montserrat
    Figols, Mariona
    Carles, Joan
    Suarez, Cristina
    Rivera, Daniel Herrero
    Gonzalez-Billalabeitia, Enrique
    Civico, Claudia
    Sala-Gonzalez, Nuria
    de Porras, Vicenc Ruiz
    Ribal, Maria J.
    Prat, Aleix
    Mellado, Begona
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (04): : 954 - 964
  • [30] Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in TP53, PTEN and RB1 on ETS gene fusions and prognosis in metastatic castrate resistant prostate cancer
    Watson, Allison P.
    Shabaneh, Ashraf
    Wang, Jinhua
    Dehm, Scott M.
    Rao, Arpit
    Ryan, Charles J.
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2020, 8 (04): : 106 - +